Recent

% | $
Quotes you view appear here for quick access.

Rockwell Medical, Inc. Message Board

forgetme22 2 posts  |  Last Activity: Jul 25, 2015 3:08 PM Member since: May 6, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Size of the hyperphosphatemia market According to the most recent data available from the U.S. Renal Data System, in 2011 there were 395,656 patients on hemodialysis in the United States. Additionally, according to the European ERA-EDTA Registry 2011 Annual Report and a study in 2010 by the Japanese Society for Dialysis Therapy, there were approximately 270,000 patients on hemodialysis in Europe and about 250,000 in Japan. We estimate, based on phosphate binder utilization, the only approved therapies for hyperphosphatemia, that there are about 270,000, 215,000 and 220,000 ESRD patients with hyperphosphatemia in the United States, Europe and Japan, respectively. The worldwide market for phosphate binders in 2011 was reported to be approximately $1.5 billion and is projected to reach $2.3 billion by 2015. Although phosphate binders are not approved by the U.S. Food and Drug Administration, or FDA, for the treatment of hyperphosphatemia in CKD patients, in other major markets such as Europe and Japan, phosphate binders are approved for the treatment of hyperphosphatemia in Stages 3 and 4 CKD patients. - See more at: http://www.ardelyx.com/phosphorus-management-in-esrd/#sthash.i91KrJrG.dpuf

  • forgetme22 by forgetme22 Jun 1, 2015 5:06 PM Flag

    2 oral presentations a asco ! Keep an eye on lung caner data. Up up away

RMTI
12.17+0.22(+1.84%)3:38 PMEDT